CLAIMS

1. A vaccine composition comprising an immunogenic peptide comprising a CD8+ T cell epitope from a polypeptide encoded by an open reading frame (ORF) present on at least part of the negative strand of segment 8 of the genome of the influenza A virus, in which the immunogenic peptide is between 8 to 40 amino acids in length and in which the T cell epitope comprises an amino acid sequence set forth in SEQ ID NOs: 16-53.

2. A vaccine composition according to Claim 1, which comprises two or more immunogenic peptides.

3. A vaccine composition according to Claim 2, which comprises two or more immunogenic peptides each comprising a different CD8+ T cell epitope from a polypeptide encoded by an open reading frame (ORF) present on at least part of the negative strand of segment 8 of the genome of the influenza A virus, in which the immunogenic peptide is between 8 to 40 amino acids in length and in which the T cell epitope comprises an amino acid sequence set forth in SEQ ID NOs: 16-53.

4. A vaccine composition according to Claim 1, 2 or 3, which comprises at least one immunogenic peptide that interacts with at least two different HLA supertypes.

5. A vaccine composition according to any preceding claim, in which the ORF is at least 85 codons in length.

6. A vaccine composition according to any preceding claim, in which the ORF is at least 167 codons in length.

7. A vaccine composition according to any preceding claim, in which the ORF is at least 216 codons in length.

8. A vaccine composition according to any preceding claim, in which the CD8+ T cell epitope is conserved between human influenza A viruses.

9. A vaccine composition according to any preceding claim, in which the CD8+ T cell epitope is conserved between human influenza A viruses and a swine, equine and/or avian influenza A virus.

10. A vaccine composition according to any preceding claim, in which the CD8+ T cell epitope is present in a predicted ORF of at least 85, at least 167 or at least 216 codons in length in a swine, equine and/or avian influenza A virus.

11. A vaccine composition according to Claim 9 or 10, in which the swine influenza A virus is of serotype H1N1.

12. A vaccine composition according to any of Claims 1 to 11 for use in a method of preventing or treating a viral infection in a human individual, in which the individual is infected with, or at risk of being infected with, an influenza A virus.

13. A vaccine composition according to Claim 12, in which the viral infection is caused by a zoonotic virus.

14. A vaccine composition according to Claim 12, in which the viral infection is a pandemic viral infection.

15. A method of identifying an immunogenic peptide comprising a CD8+ T cell epitope from an open reading frame (ORF), in which the ORF is present on at least part of the negative strand of segment 8 of the genome of the influenza A virus, by:

(a) identifying an ORF encoded by at least part of the negative strand of segment 8 of the genome of the influenza A virus;

(b) predicting the sequence of the polypeptide encoded by the ORF;

(c) assessing whether a peptide binds a MHC Class I molecule by:

(i) contacting CD8+ T cells obtained from a human individual infected with, or previously infected with, influenza A virus with the peptide; and

(ii) measuring in vitro the immune response to the peptide; and

(d) assessing whether a peptide that binds a MHC Class I molecule comprises a sequence present in the predicted sequence,

thereby identifying an immunogenic peptide comprising a CD8+ T cell epitope.

16. A method according to Claim 15, in which the ORF comprises a stop codon, the predicted sequence is predicted on the basis that the stop codon is mutated to a codon

encoding an amino acid and the peptide comprises a sequence present in a part of the predicted sequence that is C-terminal to the mutated codon.

17. A method according to Claim 15, in which the immune response is measured *in vitro* by determining interferon gamma (IFNy) production.

18. A vaccine composition according to any of Claims 1 to 5 or a vaccine composition for the use according to Claim 6, further comprising a CD4+ T cell epitope or a B cell epitope from a polypeptide encoded by an open reading frame (ORF) encoded by at least part of segment 8 of the genome of the influenza A virus.